



Eisai Inc. Medical Information

100 Tice Blvd Woodcliff Lake, NJ 07677

1-888-274-2378 • Fax: 732-791-1399 • <http://www.eisai.com/us>

Kidney Cancer Research Summit 2021, Virtual – Hybrid: Eisai Inc. Sponsored Research

Please see the listing of Eisai Inc. sponsored research presented at KCRS 2021 below and refer to the Congress Links section available on our Medical Information website which may include additional information.

RENAL CELL CARCINOMA

1. Choueiri TK, Powles T, Porta C, et al. A Phase 3 Trial of Lenvatinib Plus Pembrolizumab Versus Sunitinib as a First-Line Treatment for Patients With Advanced Renal Cell Carcinoma: Overall Survival Follow-up Analysis (the CLEAR Study). Oral Presentation at the Kidney Cancer Research Summit 2021 (KCRS21); October 7 – 8, 2021.
2. Lee CH, Li C, Perini RF, et al. Pembrolizumab With Lenvatinib in the First-Line Setting for Non-Clear Cell Renal Cell Carcinoma: Open-Label Phase 2 KEYNOTE-B61 Study. Poster presented at the Kidney Cancer Research Summit 2021 (KCRS21); October 7 – 8, 2021.
3. Rini B, Plimack E, Powles T, et al. MK-1308A + Lenvatinib and Pembrolizumab + Belzutifan + Lenvatinib Versus Pembrolizumab + Lenvatinib as First-Line Treatment for Clear Cell Renal Cell Carcinoma: A Randomized, Open-Label, Phase 3 Study. Poster presented at the Kidney Cancer Research Summit 2021 (KCRS21); October 7 – 8, 2021.
4. Motzer R, Liu Y, Perini R, et al. Randomized, Open-Label, Phase 3 Study of Belzutifan Plus Lenvatinib Versus Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Anti-PD-1/PD-L1 Therapy. Poster presented at the Kidney Cancer Research Summit 2021 (KCRS21); October 7 – 8, 2021.

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the publication(s) listed above, please submit your request via www.eisaimedicalinformation.com/oncology/medicalinquiry or the submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_oncmedinfo@eisai.com or call 1-888-274-2378.